• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

突变型 p53 在非编码 RNA 世界中的影响。

The Impact of Mutant p53 in the Non-Coding RNA World.

机构信息

IRCCS Regina Elena National Cancer Institute-IFO, Oncogenomic and Epigenetic Unit; via Elio Chianesi, 53-00144 Rome, Italy.

出版信息

Biomolecules. 2020 Mar 19;10(3):472. doi: 10.3390/biom10030472.

DOI:10.3390/biom10030472
PMID:32204575
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7175150/
Abstract

Long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), micro RNAs (miRNAs), and extracellular RNAs (exRNAs) are new groups of RNAs with regulation activities that have low or no protein-coding ability. Emerging evidence suggests that deregulated expression of these non-coding RNAs is associated with the induction and progression of diverse tumors throughout epigenetic, transcriptional, and post-transcriptional modifications. A consistent number of non-coding RNAs (ncRNAs) has been shown to be regulated by p53, the most important tumor suppressor of the cells frequently mutated in human cancer. It has been shown that some mutant p53 proteins are associated with the loss of tumor suppressor activity and the acquisition of new oncogenic functions named gain-of-function activities. In this review, we highlight recent lines of evidence suggesting that mutant p53 is involved in the expression of specific ncRNAs to gain oncogenic functions through the creation of a complex network of pathways that influence each other.

摘要

长链非编码 RNA(lncRNA)、环状 RNA(circRNA)、微小 RNA(miRNA)和细胞外 RNA(exRNA)是一组新的具有调控活性的 RNA,其蛋白编码能力较低或没有。新出现的证据表明,这些非编码 RNA 的表达失调与各种肿瘤的诱导和进展有关,涉及表观遗传、转录和转录后修饰。大量的非编码 RNA(ncRNA)被证明受到 p53 的调控,p53 是人类癌症中经常发生突变的细胞中最重要的肿瘤抑制因子。已经表明,一些突变型 p53 蛋白与肿瘤抑制活性的丧失和获得新的致癌功能(称为获得性功能)有关。在这篇综述中,我们强调了最近的证据表明,突变型 p53 参与特定 ncRNA 的表达,通过创建相互影响的复杂通路网络获得致癌功能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5062/7175150/2e9ce22b6a16/biomolecules-10-00472-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5062/7175150/2e9ce22b6a16/biomolecules-10-00472-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5062/7175150/2e9ce22b6a16/biomolecules-10-00472-g001.jpg

相似文献

1
The Impact of Mutant p53 in the Non-Coding RNA World.突变型 p53 在非编码 RNA 世界中的影响。
Biomolecules. 2020 Mar 19;10(3):472. doi: 10.3390/biom10030472.
2
Non-coding RNAs, guardians of the p53 galaxy.非编码 RNA,守护 p53 星系。
Semin Cancer Biol. 2021 Oct;75:72-83. doi: 10.1016/j.semcancer.2020.09.002. Epub 2020 Sep 11.
3
Emerging Role of Non-Coding RNAs in Esophageal Squamous Cell Carcinoma.非编码 RNA 在食管鳞状细胞癌中的新兴作用。
Int J Mol Sci. 2019 Dec 30;21(1):258. doi: 10.3390/ijms21010258.
4
Emerging role of non-coding RNA in oral cancer.非编码 RNA 在口腔癌中的新兴作用。
Cell Signal. 2018 Jan;42:134-143. doi: 10.1016/j.cellsig.2017.10.009. Epub 2017 Oct 19.
5
MicroRNA Control of p53.微小RNA对p53的调控
J Cell Biochem. 2017 Jan;118(1):7-14. doi: 10.1002/jcb.25609. Epub 2016 Jun 3.
6
The potential role of circular RNAs in regulating p53 in different types of cancers.环状 RNA 在不同类型癌症中调控 p53 的潜在作用。
Pathol Res Pract. 2024 Sep;261:155488. doi: 10.1016/j.prp.2024.155488. Epub 2024 Jul 25.
7
Emerging roles of non-coding RNAs in epigenetic regulation.非编码 RNA 在表观遗传调控中的新兴作用。
Sci China Life Sci. 2016 Mar;59(3):227-35. doi: 10.1007/s11427-016-5010-0. Epub 2016 Jan 29.
8
Combinatorial epigenetic regulation of non-coding RNAs has profound effects on oncogenic pathways in breast cancer subtypes.组合表观遗传调控非编码 RNA 对乳腺癌亚型致癌途径有深远影响。
Brief Bioinform. 2018 Jan 1;19(1):52-64. doi: 10.1093/bib/bbw099.
9
Long non-coding RNA NEAT1 is a transcriptional target of p53 and modulates p53-induced transactivation and tumor-suppressor function.长链非编码RNA NEAT1是p53的转录靶点,可调节p53诱导的反式激活和肿瘤抑制功能。
Int J Cancer. 2017 Jun 15;140(12):2785-2791. doi: 10.1002/ijc.30689. Epub 2017 Mar 27.
10
The decalog of long non-coding RNA involvement in cancer diagnosis and monitoring.长非编码 RNA 参与癌症诊断和监测的十诫。
Crit Rev Clin Lab Sci. 2014 Dec;51(6):344-57. doi: 10.3109/10408363.2014.944299. Epub 2014 Aug 15.

引用本文的文献

1
The Interplay Between Oxidant/Antioxidant System, Transcription Factors, and Non-Coding RNA in Lung Cancer.肺癌中氧化还原系统、转录因子与非编码RNA之间的相互作用
Int J Mol Sci. 2025 Aug 8;26(16):7679. doi: 10.3390/ijms26167679.
2
Construction and validation of a prognostic signature based on microvascular invasion and immune-related genes in hepatocellular carcinoma.基于微血管侵犯和免疫相关基因构建并验证肝癌的预后signature。
Sci Rep. 2024 Nov 6;14(1):26994. doi: 10.1038/s41598-024-78467-3.
3
Construction of a TP53 mutation-associated ceRNA network as prognostic biomarkers in hepatocellular carcinoma.

本文引用的文献

1
MicroRNA-Based Combinatorial Cancer Therapy: Effects of MicroRNAs on the Efficacy of Anti-Cancer Therapies.基于 microRNA 的癌症联合治疗:microRNAs 对癌症治疗效果的影响。
Cells. 2019 Dec 20;9(1):29. doi: 10.3390/cells9010029.
2
Towards the overcoming of anticancer drug resistance mediated by p53 mutations.克服由 p53 突变介导的抗癌药物耐药性。
Drug Resist Updat. 2020 Mar;49:100671. doi: 10.1016/j.drup.2019.100671. Epub 2019 Nov 30.
3
The Role of Non-coding RNAs in Oncology.非编码 RNA 在肿瘤学中的作用。
构建作为肝细胞癌预后生物标志物的TP53突变相关ceRNA网络
Heliyon. 2024 Apr 30;10(9):e30066. doi: 10.1016/j.heliyon.2024.e30066. eCollection 2024 May 15.
4
Deciphering the Role of p53 and TAp73 in Neuroblastoma: From Pathogenesis to Treatment.解读p53和TAp73在神经母细胞瘤中的作用:从发病机制到治疗
Cancers (Basel). 2022 Dec 16;14(24):6212. doi: 10.3390/cancers14246212.
5
Li-Fraumeni Syndrome: Mutation of Is a Biomarker of Hereditary Predisposition to Tumor: New Insights and Advances in the Treatment.李-弗劳梅尼综合征: 是肿瘤遗传性易感性的生物标志物突变:治疗的新见解与进展
Cancers (Basel). 2022 Jul 27;14(15):3664. doi: 10.3390/cancers14153664.
6
p53-Mediated Indirect Regulation on Cellular Metabolism: From the Mechanism of Pathogenesis to the Development of Cancer Therapeutics.p53介导的细胞代谢间接调控:从发病机制到癌症治疗的发展
Front Oncol. 2022 May 30;12:895112. doi: 10.3389/fonc.2022.895112. eCollection 2022.
7
Construction and Validation of a Ferroptosis-Related lncRNA Signature as a Novel Biomarker for Prognosis, Immunotherapy and Targeted Therapy in Hepatocellular Carcinoma.构建和验证一种与铁死亡相关的lncRNA特征作为肝细胞癌预后、免疫治疗和靶向治疗的新型生物标志物
Front Cell Dev Biol. 2022 Feb 22;10:792676. doi: 10.3389/fcell.2022.792676. eCollection 2022.
8
Novel insights into the mechanisms by which lncRNA HOTAIR regulates migration and invasion in HeLa cells.长链非编码 RNA HOTAIR 调控 HeLa 细胞迁移和侵袭的作用机制的新见解。
Cell Cycle. 2022 Mar-Mar;21(6):602-617. doi: 10.1080/15384101.2022.2030167. Epub 2022 Jan 28.
9
Regulation of miRNAs Expression by Mutant p53 Gain of Function in Cancer.癌症中突变型p53功能获得对miRNAs表达的调控
Front Cell Dev Biol. 2021 Dec 6;9:695723. doi: 10.3389/fcell.2021.695723. eCollection 2021.
10
Long Non-Coding RNAs in Epithelial-Mesenchymal Transition of Pancreatic Cancer.长链非编码RNA在胰腺癌上皮-间质转化中的作用
Front Mol Biosci. 2021 Nov 8;8:717890. doi: 10.3389/fmolb.2021.717890. eCollection 2021.
Cell. 2019 Nov 14;179(5):1033-1055. doi: 10.1016/j.cell.2019.10.017.
4
The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas.miR-205-5p/BRCA1/RAD17轴促进头颈部鳞状细胞癌的基因组不稳定。
Cancers (Basel). 2019 Sep 11;11(9):1347. doi: 10.3390/cancers11091347.
5
Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response.p53 突变型乳腺癌的内在阿霉素耐药性与 miR-30c/FANCF/REV1 介导的 DNA 损伤反应有关。
Cell Death Dis. 2019 Sep 11;10(9):666. doi: 10.1038/s41419-019-1871-z.
6
P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.P53-R273H 突变通过调节特定的长链非编码 RNA 增强结直肠癌干细胞特性。
J Exp Clin Cancer Res. 2019 Aug 28;38(1):379. doi: 10.1186/s13046-019-1375-9.
7
Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies.细胞外液中的非编码RNA作为癌症生物标志物:液体活检的新前沿
Cancers (Basel). 2019 Aug 14;11(8):1170. doi: 10.3390/cancers11081170.
8
The biogenesis, biology and characterization of circular RNAs.环状 RNA 的生物发生、生物学和特征。
Nat Rev Genet. 2019 Nov;20(11):675-691. doi: 10.1038/s41576-019-0158-7. Epub 2019 Aug 8.
9
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.癌症基因组图谱中 TP53 基因与通路改变的综合分析。
Cell Rep. 2019 Jul 30;28(5):1370-1384.e5. doi: 10.1016/j.celrep.2019.07.001.
10
Gain-of-function mutant p53: history and speculation.功能获得性突变型p53:历史与推测
J Mol Cell Biol. 2019 Jul 19;11(7):605-609. doi: 10.1093/jmcb/mjz067.